Expert opinion on emerging drugs: chronic low back pain

Bibliography

• US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608
   PubMed Web of Science ®Google Scholar
• Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012;64:2028-37
   PubMed Web of Science ®Google Scholar
• Juniper M, Le T, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother 2009;10:2581-92
   PubMed Web of Science ®Google Scholar
• Crow W, Willis D. Estimating cost of care for patients with acute low back pain: a retrospective review of patient records. J Am Osteopath Assoc 2009;109:229-33
   PubMedGoogle Scholar
• Pizzo PA, Clark NM, Carter-Pokras O, et al. Relieving pain in America. A blueprint for transforming prevention, care, education and research. Institute of Medicine. National Academies Press; 2011
   Google Scholar
• Cohen SP, Mao J. Mechanisms of neuropathic pain and their clinical implications. BMJ 2014;348:f7656
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Waddell G. A new clinical model for the treatment of low-back pain. Spine (Phila Pa 1976) 1987;12(7):631
   Google Scholar
• Keller A, Hayden J, Bombardier C, van Tulder M. Effect sizes of non-surgical treatments of non-specific low-back pain. Eur Spine J 2007;16:1776-88
   PubMed Web of Science ®Google Scholar
• Hassan A, Saleh H, Baroudy Y, et al. Prevalence of neuropathic pain among patients suffering from chronic low back pain in Saudi Arabia. Saudi Med J 2004;25:1986-90
   PubMed Web of Science ®Google Scholar
• Cohen SP, Jamison D, Bicket M, et al. Epidural steroids: a comprehensive, evidence-based review. Reg Anesth Pain Med 2013;38:175-200
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001;95:241-9
   PubMed Web of Science ®Google Scholar
• Farrar JT. What is clinically meaningful: outcome measures in pain clinical trials. Clin J Pain 2000;16(2 Suppl):S106-12
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-8
   PubMed Web of Science ®Google Scholar
• Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet 2014;384(9954):1586-96
   PubMed Web of Science ®Google Scholar
• Khoromi S, Cui L, Nackers L, et al. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;130:66-75
   PubMed Web of Science ®Google Scholar
• Baron R, Freynhagen R, Tölle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-7
   PubMed Web of Science ®Google Scholar
• Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008;CD000396
   Google Scholar
• Deshpande A, Furlan A, Mailis-Gagnon A, et al. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;CD004959
   Google Scholar
• Urquhart DM, Hoving JL, Assendelft WW, et al. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev 2008;CD001703
   Google Scholar
• Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004;26:1355-67
   PubMed Web of Science ®Google Scholar
• Morlion B. Chronic low back pain: pharmacological, interventional and surgical strategies. Nat Rev Neurol 2013;9(8):462-73
   PubMed Web of Science ®Google Scholar
• Freburger JK, Homes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med 2009;169(3):251-8
   PubMed Web of Science ®Google Scholar
• Smith M, Davis MA, Stano M, Whedon JM. Aging baby boomers and the rising cost of chronic back pain: secular trend analysis of longitudinal medical expenditures panel survey data for years to 2000 to 2007. J Manipulative Physiol Ther 2013;36:2-11
   PubMed Web of Science ®Google Scholar
• Driscoll T, Jacklyn G, Orchard J, et al. The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;3(6):975-81
   Google Scholar
• Luo X, Pietrobon R, Hey L. Patterns and trends in opioid use among individuals with back pain in the united states. Spine 2004;29:884-91
   PubMed Web of Science ®Google Scholar
• Caudill-Slosberg M, Schwartz L, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain 2004;109(3):514-19
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs: overdose of prescription opioid pain relievers – United States, 1999 – 2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-92
   PubMedGoogle Scholar
• Chou R, Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med; 2007;147(7):505-14
   Google Scholar
• Manchikanti L, Falco FJ, Singh V, et al. Utilization of interventional techniques in managing chronic pain in the Medicare population: analysis of growth patterns from 2000 to 2011. Pain Physician 2012;15:E969-82
   PubMed Web of Science ®Google Scholar
• Deyo RA, Gray DT, Kreuter W, et al. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976) 2005;30(12):1441-5
   PubMed Web of Science ®Google Scholar
• Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother 2013;13:99-116
   PubMed Web of Science ®Google Scholar
• Cohen SP, Huang JH, Brummett C. Facet joint pain- advances in patient selection and management. Nat Rev Rheumatol 2013;9:101-16
   PubMed Web of Science ®Google Scholar
• Jacobs WC, van Tulder M, Arts M, et al. Surgery versus conservative management of sciatica due to a lumbar herniated disc: a systematic review. Eur Spine J 2011;20:513-22
   PubMed Web of Science ®Google Scholar
• Kovacs FM, Urrútia G, Alarcón JD. Surgery versus conservative treatment for symptomatic lumbar spinal stenosis: a systematic review of randomized controlled trials. Spine (Phila Pa 1976) 2011;36:E1335-51
   PubMed Web of Science ®Google Scholar
• Brox JI, Nygaard ØP, Holm I, et al. Four-year follow-up of surgical versus non-surgical therapy for chronic low back pain. Ann Rheum Dis 2010;69:1643-8
   PubMed Web of Science ®Google Scholar
• Henschke N, Ostelo RW, van Tulder MW, et al. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev 2010;7(7):CD002014
   PubMedGoogle Scholar
• van Tulder M, Malmivaara A, Esmail R, et al. Exercise therapy for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine 2000;25:2784-96
   PubMed Web of Science ®Google Scholar
• Skjarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11(12):1282-90
   PubMed Web of Science ®Google Scholar
• Cawston H, Davie A, Paget MA, et al. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. Eur Spine J 2013;22(9):1996-2009
   PubMed Web of Science ®Google Scholar
• Moore RA, Cai N, Skjarevski V, et al. Duloxetine use in chronic painful conditions – individual patient data responder analysis. Eur J Pain 2014;18:67-75
   PubMed Web of Science ®Google Scholar
• Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta. GBI Research, London, UK. Available from: http://www.gbiresearch.com/Report.aspx?ID=Pain-Management-Therapeutics-Market-to-2017-Price-Competition-to-Intensify-Following-Patent-Expiries-of-Lyrica-and-Cymbalta& [Last accessed 1 October 2014]
   Google Scholar
• Pfizer Annual Report 2013. Pfizer, Inc., New York, NY. Available from: http://www.pfizer.com/files/investors/financial_reports/annual_reports/2013/stories_fight.htm [Last accessed 1 October 2014]
   Google Scholar
• Eli Lilly and Company Annual Report 2013. Eli Lilly and Company. Indianapolis, IN. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=822044 [Last accessed 1 October 2014]
   Google Scholar
• Actavis Confirms Generic Nucynta® ER Patent Challenge. PR Newswire, New York, NY. Available from: http://www.prnewswire.com/news-releases/actavis-confirms-generic-nucynta-er-patent-challenge-217368391.html [Last accessed 1 October 2014]
   Google Scholar
• Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001;344(5):363-70
   PubMed Web of Science ®Google Scholar
• Bennett MI, Smith BH, Torrance N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005;6(3):149-58
   PubMed Web of Science ®Google Scholar
• Cohen SP, Kapoor SG, Rathmell JP. Intravenous infusion tests have limited utility for selecting long-term drug therapy in patients with chronic pain: a systematic review. Anesthesiology 2009;111:416-31
   PubMed Web of Science ®Google Scholar
• Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg 2012;115:428-42
   PubMed Web of Science ®Google Scholar
• Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 2009;143:169-71
   PubMed Web of Science ®Google Scholar
• Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987;147:1442-4
   PubMed Web of Science ®Google Scholar
• Melnikova I. Pain market. Nat Rev Drug Discov 2010;9:589-90
   PubMed Web of Science ®Google Scholar
• A Brief Overview of Risk Evaluation & Mitigation Strategies (REMS). FDA Review. FDA/Center for Drug Evaluation and Research, Washington, DC; 2012. Available from: http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf [Last accessed 1 October 2014]
   Google Scholar
• Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain 2014;154(1):S94-100
   Google Scholar
• Vokow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies – tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6
   PubMed Web of Science ®Google Scholar
• Extended-Release and Long-Acting Opioid Analgesics - RISK EVALUATION AND MITIGATION STRATEGY (REMS). FDA Review. FDA/Center for Drug Evaluation and Research, Washington, DC; 2012. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM348818.pdf [Last accessed 1 October 2014]
   Google Scholar
• Marco JL, Amariles P, Boscáet B, et al. Risk factors associated with NSAID-induced upper gastrointestinal bleeding resulting in hospital admissions: a cross-sectional, retrospective, case series analysis in valencia, spain. Curr Ther Res Clin Exp 2007;68(2):107-19
   PubMed Web of Science ®Google Scholar
• Rahme E, Joseph L, Kong S, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24
   PubMed Web of Science ®Google Scholar
• Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy Experience in a US health maintenance organisation. Pharmacoeconomics 1997;12(1):76-88
   PubMed Web of Science ®Google Scholar
• de Pouvourville G, Tasch RF. The economic consequences of NSAID-induced gastrointestinal damage. Eur J Rheumatol Inflamm 1993;13(1):33-40
   PubMedGoogle Scholar
• Bloom BS. Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Aliment Pharmacol Ther 1988;2(Suppl 1):131-8
   PubMedGoogle Scholar
• Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11):1-278. iii
   PubMed Web of Science ®Google Scholar
• Le Goff B, Berthelot JM, Maugars Y, et al. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010;16(27):3045-52
   PubMed Web of Science ®Google Scholar
• O’Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev 2011(11):CD009416
   Google Scholar
• Patte-Mensah C, Cherkaouia K, Boudard D, et al. Neurogenic pain and steroid synthesis in the spinal cord. J Mol Neurosci 2006;28(1):17-31
   PubMed Web of Science ®Google Scholar
• Chen SC, Liu BC, Chen CW, et al. Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats. Biochem Biophys Res Commun 2006;349(2):626-33
   PubMed Web of Science ®Google Scholar
• Pappagallo M, Breuer B, Lin HM, et al. A pilot trial of intravenous pamidronate for chronic low back pain. Pain 2014;1):108-17
   PubMed Web of Science ®Google Scholar
• Ohtori S, Akazawa T, Murata Y, et al. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 2010;17(2):209-13
   PubMed Web of Science ®Google Scholar
• Zhu M, Liang R, Pan LH, et al. Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials. Pain Med 2013;14(2):257-64
   PubMed Web of Science ®Google Scholar
• Gilron I, Dickenson A. Emerging drugs for neuropathic pain. Expert Opin Emerg Drugs 2014;1-13
   PubMedGoogle Scholar
• Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs 2011;16(3):479-91
   PubMed Web of Science ®Google Scholar
• Cohen SP, Raja SN. Pathogenesis, Diagnosis, and Treatment of Lumbar Zygapophysial (Facet) Joint Pain. Anesthesiology 2007;106(3):591-614
   PubMed Web of Science ®Google Scholar
• Siedel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010;40(2):109-26
   PubMed Web of Science ®Google Scholar
• Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of nerve growth factor. Trends Pharmacol Sci 2006;27(2):85-91
   PubMedGoogle Scholar
• Watson JJ, Allen SJ, Dawbarn DD, et al. Targeting nerve growth factor in pain. BioDrugs 2008;22(6):349-59
   PubMed Web of Science ®Google Scholar
• Seidel MF, Wise BL, Lane NE. Nerve growth factor: update on science and therapy. Osteoarthritis Cartilage 2013;21(9):1223-8
   PubMed Web of Science ®Google Scholar
• Lewin GR, Lechner SG, Smith ES. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. Handb Exp Pharmacol 2014;220:251-82
   PubMedGoogle Scholar
• Sanga P, Katz N, Polverejan E, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain 2013;154(10):1910-19
   PubMed Web of Science ®Google Scholar
• Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011;152(10):2248-58
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain 2013;154(7):1009-21
   PubMed Web of Science ®Google Scholar
• Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program; Some Studies Continue In Areas Of Unmet Medical Need. Pfizer Corporate Press Release, New York, 2010. Available from: http://pfizer.mediaroom.com/index.php?s=5149&item=11206 [Last accessed 1 October 2014]
   Google Scholar
• Eli Lilly and Company 2nd Qtr Result. Indianapolis, IN. 2014. Slide 14 Available from: http://files.shareholder.com/downloads/LLY/3119382919x0x770508/e97384ea-95d8-4661-81ae-3284a6ffec30/Q2_2014_Slides.pdf [Last accessed 1 October 2014]
   Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 2014;74(6):619-26
   PubMed Web of Science ®Google Scholar
• Mika J, Zychowska M, Popiolk-Barczyk K, et al. Importance of glial activation in neuropathic pain. Eur J Pharmacol 2013;716(1-3):106-19
   PubMed Web of Science ®Google Scholar
• Hameed H, Hameed M, Christo PJ. The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs. Curr Pain Headache Rep 2010;96-104
   PubMed Web of Science ®Google Scholar
• Rolan P. Methods for targeting glial activation in the treatment of patients with chronic pain. Presented at the Mechanisms and Treatment of Neuropathic Pain Annual Meeting; Snowbird, Utah, USA; 1-3 November 2007
   Google Scholar
• Olmarker K, Nutu M, Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 2003;28:1635-42
   PubMed Web of Science ®Google Scholar
• Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity. Possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001;26:863-9
   PubMed Web of Science ®Google Scholar
• Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 2014;74:1379-410
   PubMed Web of Science ®Google Scholar
• Korhonen T, Karppinen J, Malmivaara A, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 2004;29(19):2115-19
   PubMed Web of Science ®Google Scholar
• Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006;31(24):2759-66
   PubMed Web of Science ®Google Scholar
• Genevay S, Atlas SJ, Katz JN. Variation in eligibility criteria from studies of radiculopathy due to a herniated disc and of neurogenic claudication due to lumbar spinal stenosis: a structured literature review. Arthritis Rheum 2010;35(7):803-11
   Google Scholar
• Okoro T, Tafazal S, Longworth S, et al. Tumor necrosis alpha-blocking agent (Etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica. J Spin Disorder Tech 2010;23(1):74-7
   PubMed Web of Science ®Google Scholar
• Cohen SP, White RL, Kurihara C, et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012;156(8):551-9
   PubMed Web of Science ®Google Scholar
• Kume K, Amano S, Yamada S. The efficacy and safety of caudal epidural injection with the TNF-alpha antagonist, etanercept, in patients with disc-herniation-incduced sciatica. Results of a randomized, controlled, 1-month follow-up study. Ann Rheum Dis 2008;67(Suppl II):131
   PubMedGoogle Scholar
• Ohtori S, Miyagi M, Eguchi Y, et al. Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine 2012;37(6):439-44
   PubMed Web of Science ®Google Scholar
• Freeman BJ, Ludbrook GL, Hall S, et al. Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation. Spine 2013;38(23):1986-94
   PubMed Web of Science ®Google Scholar
• Marks DM, Shah MJ, Patkar AA, et al. Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: premise and Promise. Curr Neuropharmacol 2009;7(4):331-6
   PubMed Web of Science ®Google Scholar
• Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008;68(18):2611-32
   PubMed Web of Science ®Google Scholar
• Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent and chronic pain. J Pharmacol Exp Ther 2007;321:1208-25
   PubMed Web of Science ®Google Scholar
• Riff D, Huang N, Czobor P, et al. A five-day, multi-center, randomized, placebo-controlled, double-blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain. J Pain 2005;7(2):S40
   Google Scholar
• Krieter PA, et al. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 2007;36:252-9
   PubMed Web of Science ®Google Scholar
• Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance, compliance, compliance. Mol Interv 2011;11(2):107-10
   PubMed Web of Science ®Google Scholar
• Gilron I. Drug discovery for neuropathic pain. In: Simpson DM, McArthur JC, Dworkin RH, editors. Neuropathic pain: mechanisms, diagnosis, and treatment. Oxford University Press; NY, USA: 2012. p. 38-57
   Google Scholar
• Nicotra L, Loram LC, Watkins LR, et al. Toll-like receptors in chronic pain. Exp Neurol 2012;234(2):316-29
   PubMed Web of Science ®Google Scholar
• Liu T, Gao Y, Ji R. Emerging role of Toll-like receptors in the control of pain and itch. Neurosci Bull 2012;28(2):131-44
   PubMedGoogle Scholar
• Connolly DJ, O’Neill LA. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012;12(4):510-18
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol 2014;32(16):1655-61
   PubMed Web of Science ®Google Scholar
• Przewłocki R, Przewłocka B. Opioids in chronic pain. Eur J Pharmacol 2001;429(1):79-91
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2011;42:903-17
   PubMed Web of Science ®Google Scholar
• Yarlas A, Miller K, Wen W, et al. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. J Pain 2013;14:14-23
   PubMed Web of Science ®Google Scholar
• Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000;93(5):1345-9
   PubMed Web of Science ®Google Scholar
• Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212
   PubMed Web of Science ®Google Scholar
• Szallasi A, Blumberg PM. [3H]resiniferatoxin binding by the vanilloid receptor species-related differences, effects of temperature and sulhydryl reagents. Naunyn Schmiedebergs Arch Pharmacol 1993;347:84-91
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24
   PubMed Web of Science ®Google Scholar
• Hayes P, Meadows HJ, Gunthorpe MJ, et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2000;88:205-15
   PubMed Web of Science ®Google Scholar
• Steenland HW, Ko SW, Wu LJ, et al. Hot receptors in the brain. Mol Pain 2006;2:34
   PubMed Web of Science ®Google Scholar
• Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TPRV1. An update. Eur J Biochem 2004;271:1814-19
   PubMedGoogle Scholar
• Gunthorpe MJ, Benham CD, Randall A, et al. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002;23:183-91
   PubMed Web of Science ®Google Scholar
• Starowicz K, Nigam S, Di Marzo V, et al. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007;114:13-33
   PubMed Web of Science ®Google Scholar
• Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004;500:231-4
   PubMed Web of Science ®Google Scholar
• Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68
   PubMed Web of Science ®Google Scholar
• Keeble J, Russell F, Curtis B, et al. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum 2005;52:3248-56
   PubMed Web of Science ®Google Scholar
• Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides 2004;32:377-84
   Google Scholar
• Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol 2000;292:R64-76
   Google Scholar
• Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000;405:183-7
   PubMed Web of Science ®Google Scholar
• Menendez L, Juarez L, Garcia E, et al. Analgesic effects of capasazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006;393:70-3
   PubMed Web of Science ®Google Scholar
• Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60(1):267-77
   PubMed Web of Science ®Google Scholar
• Knotkova H, Pappagallo M, Szallasi A, et al. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008;24:142-54
   PubMed Web of Science ®Google Scholar
• Cantillon M, Vause E, Sykes D, et al. Safety, tolerability and efficacy of intraoperative ALGRX 4975 in a randomized, double-blind, placebo-controlled study of subjects undergoing bunionectomy. J Pain 2005;6:S48
   PubMedGoogle Scholar
• Diamond E, Richards P, Miller T. ALGRX 4975 reduces pain of intermetatarsal neuroma: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J Pain 2006;7:S41
   Google Scholar
• Richards P, Vasko G, Stasko I, et al. ALGRX 4975 reduces pain of acute lateral epicondylitis: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J Pain 2006;7:S3
   PubMedGoogle Scholar
• Cantillon M, Vause E, Sykes D, et al. Safety, tolerability and efficacy of ALGRX 4975 in Osteoarthritis (OA) of the knee. J Pain 2005;6:S39
   Google Scholar
• Cantillon M, Vause E, Sykes D, et al. Preliminary safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. J Pain 2005;6:S39
   Google Scholar
• Chen TY, Corcos J, Camel M, et al. Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct 2005;16:293-7
   PubMed Web of Science ®Google Scholar
• Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005;173:1590-4
   PubMed Web of Science ®Google Scholar
• Honore P, Wismer CT, Mikusa J, et al. A-425619 [1-isoquinolin-5-yl-3-(-trifluromethyl-benzyl)-urea], a novel transient receptor potential receptor type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-21
   PubMed Web of Science ®Google Scholar
• Gavva NR, Tamir R, Qu Y, et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor (TPRV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005;313:474-84
   PubMed Web of Science ®Google Scholar
• Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective, orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006;16:3287-91
   PubMed Web of Science ®Google Scholar
• Walker KM, Urban L, Medhurst SJ, et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;304:56-62
   PubMed Web of Science ®Google Scholar
• Pomonis JD, Harrison JE, Mark L, et al. N-(4-tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)ttrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:387-93
   PubMed Web of Science ®Google Scholar
• Gunthrope MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009;14:56-67
   PubMed Web of Science ®Google Scholar
• Trevisani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain J 2013;6(Suppl 1):108-18
   Google Scholar
• Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-10
   PubMed Web of Science ®Google Scholar
• Othman AA, Nothaft W, Awni WM, et al. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials. J Clin Pharmacol 2012;52(7):1028-41
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Nothaft W, Duan WR, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 2011;152(2):1192-200
   PubMedGoogle Scholar
• Nash MS, McIntyre P, Groarke A, et al. BCTP, a classic polymodal inhibitor of TRPV1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. J Pharmacol Exp Ther 2012;342(2):389-98
   PubMed Web of Science ®Google Scholar
• Watabiki T, Kiso T, Kuramochi T, et al. Amerljoiration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. J Pharmacol Exp Ther 2011;336(3):743-50
   PubMed Web of Science ®Google Scholar
• Benzon H, Raja SN, Fishman SM, et al. Essentials of pain medicine. Elsevier; Philadelphia: 2011
   Google Scholar
• Jeftinija S, Jeftnija K, Liu F, et al. Excitatory amino acids are released from rat primary afferent neurons in vitro. Neurosci Lett 1991;125:191-4
   PubMed Web of Science ®Google Scholar
• Cumberbatch MJ, Chizh BA, Headley PM. AMPA receptors have an equal role in spinal nociceptive and non-nociceptive transmission. Neuroreport 1994;5:877-80
   PubMed Web of Science ®Google Scholar
• King AE, Lopez-Garcia JA. Excitatory amino acide receptor mediated neurotransmission from cutaneous afferents in rat dorsal horn in vitro. J Physiol 1993;472:443-57
   PubMed Web of Science ®Google Scholar
• Chizh BA, Headley PM. NMDA antagonists and neuropathic pain - multiple drug targets and multiple uses. Curr Pharm Des 2005;11(23):2977-94
   PubMed Web of Science ®Google Scholar
• Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998;18:2954-61
   PubMed Web of Science ®Google Scholar
• Childers WE, Reinhardt BB. N-methyl-d-aspartate antagonists and neuropathic pain: the search for relief. J Med Chem 2007;50(11):2557-62
   PubMed Web of Science ®Google Scholar
• Jones MW, McClean M, Parsons CG, et al. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurons. Neuropharmacology 2001;41:50-61
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomized controlled crossover trial with integral n-of-1 design. Pain 1994;59:127-33
   PubMed Web of Science ®Google Scholar
• Santangelo RM, Acker TM, Zimmerman SS, et al. Novel NMDA receptor modulators: an update. Expert Opin Ther Patents 2012;22(11):1337-52
   PubMed Web of Science ®Google Scholar
• Nikolajsen L, Gotrup H, Kristensen AG, et al. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized double-blinded, cross-over study. Anesth Analg 2000;91:960-6
   PubMed Web of Science ®Google Scholar
• Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002;96:1053-61
   PubMed Web of Science ®Google Scholar
• Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-18
   PubMed Web of Science ®Google Scholar
• Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71-8
   PubMed Web of Science ®Google Scholar
• Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001;22:636-42
   PubMed Web of Science ®Google Scholar
• Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-38
   PubMed Web of Science ®Google Scholar
• Sang CN, Weaver JJ, Jinga L, et al. The NR2B subunit-selective NMDA receptor antagonist, CP-101-606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Society of Neuroscience Abstract; 2003. 814.9
   Google Scholar
• Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998;50:597-664
   PubMed Web of Science ®Google Scholar
• Wallace MS, Rowbotham MC, Katz NP, et al. A randomized, double-blind, placebo controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002;59:1694-700
   PubMed Web of Science ®Google Scholar
• Sulayman DD, Yang Y, Waxman J. The NaV1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013;14:49-62
   PubMed Web of Science ®Google Scholar
• Fischer TZ, Gilmore ES, Estacion M, et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 2009;65:733-41
   PubMed Web of Science ®Google Scholar
• PROPANE STUDY: Probing the Role of Sodium Channels in Painful Neuropathies Brussels, Belgium: European Commission Research & Innovation. 2014. Available from: http://ec.europa.eu/research/health/medical-research/brain-research/projects/propane-study_en.html [Last accessed 1 October 2014]
   Google Scholar
• Hughes JP, Chessell I, Malamut R, et al. Understanding chronic inflammatory and neuropathic pain. Ann NY Acad Sci 2012;1255:30-44
   PubMed Web of Science ®Google Scholar
• McCleane G. Does gabapentin have an analgesic effect on background movement and referred pain? A randomised, double-blind, placebo controlled study. Pain Clinic 2001;13:103-7
   Web of Science ®Google Scholar
• Yildirim K, Sisecioglu M, Karatay S, et al. The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clinic 2003;15:213-18
   Web of Science ®Google Scholar
• Romano CL, et al. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009;10(4):185-91
   PubMedGoogle Scholar
• Baron R, Kern U, Müller M, et al. Effectiveness and tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized phase 3b study. Pain Pract 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Yaksh T. Calcium channels as therapeutic targets in neuropathic pain. J Pain 2006;7(1):S13-30
   PubMed Web of Science ®Google Scholar
• Maier C, Gockel HH, Gruhn K, et al. Increased risk of suicide under intrathecal ziconotide tredatment? – A warning". Pain 2010;152(1):235-7
   PubMed Web of Science ®Google Scholar
• Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 2014;17(2):153-63
   PubMed Web of Science ®Google Scholar
• Aley KO, McCarter G, Levine JD, et al. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 1998;18:7008-14
   PubMed Web of Science ®Google Scholar
• Jain NK, Patil CS, Singh A, et al. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003;67(3):150-6
   PubMed Web of Science ®Google Scholar
• Rocha FA, Silva FSJr, Leite AC, et al. Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release. Br J Pharmacol 2011;164(2b):828-35
   PubMed Web of Science ®Google Scholar
• Huang LJ, Yoon MH, Choi JI, et al. Effect of sildenafil on neuropathic pain and hemodynamics in rats. Yonsei Med J 2010;51(1):82-7
   PubMed Web of Science ®Google Scholar
• Yoon MH, Park KD, Lee HG, et al. Additive antinociception between intrathecal sildenafil and morphine in the rat formalin test. J Korean Med Sci 2008;23(6):1033-8
   PubMed Web of Science ®Google Scholar
• Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol 2011;70:207-12
   PubMed Web of Science ®Google Scholar
• Mamet J, Klukinov M, Yaksh T, et al. Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury. Pain 2014;155(2):322-33
   PubMed Web of Science ®Google Scholar
• Hao S, Mata M, Glorioso JC, et al. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 2007;14:1010-16
   PubMed Web of Science ®Google Scholar
• Ebert AD, Yu J, Rose FFJr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2008;457(7227):277-80
   PubMed Web of Science ®Google Scholar
• Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67(10):1187-94
   PubMed Web of Science ®Google Scholar
• Braz JM, Sharif-Naeini R, Vogt D, et al. Forebrain GABAergic neuron precursors integrate into adult spinal cord and reduce injury-induced neuropathic pain. Neuron 2012;74(4):663-75
   PubMed Web of Science ®Google Scholar
• Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV) (Disc_allo). National Institutes of Health/ClinicalTrials.gov, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01860417?term=stem+cell+AND+pain&no_unk=Y&rank=2 [Last accessed 1 October 2014]
   Google Scholar
• Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain. National Institutes of Health/ClinicalTrials.gov, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01290367?term=stem+cell+AND+pain&no_unk=Y&rank=3 [Last accessed 1 October 2014]
   Google Scholar
• Dworkin RH, Thakur R, Griesing T, et al. Randomized clinical trials of pregabalin for neuropathic pain: methods, results, and implications. Prog Neurother Neuropsychopharm 2008;3:167-87
   Google Scholar
• Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005;65:S32-49
   PubMed Web of Science ®Google Scholar
• Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-13
   PubMed Web of Science ®Google Scholar
• XenoPort, Inc. Phase II results for GSK1838262 (XP13512) reported for neuropathic pain associated with diabetic peripheral neuropathy. 2009. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=187883&p=irol-newsArticle&ID=1280577&highlight=
   Google Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012;153:1148-58
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. E10: Choice of control groups and related issues in clinical trials. 2001. Available from: http://www.fda.gov.ezproxy.welch.jhmi.edu/downloads/RegulatoryInformation/Guidances/ucm125912.pdf [Accessed 23 August 2014]
   Google Scholar
• Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 2005;117:450-61
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-5
   PubMed Web of Science ®Google Scholar
• Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28:140-75
   PubMed Web of Science ®Google Scholar
• Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med 2002;162:19-24
   PubMed Web of Science ®Google Scholar
• Khoromi S, Patsalides A, Parada S, et al. Topiramate in chronic lumbar radicular pain. J Pain 2005;6:829-36
   PubMed Web of Science ®Google Scholar
• Roy A. How the FDA Stifles New Cures, Part II: 90% of Clinical Trial Costs are Incurred in Phase III. Available from: http://www.forbes.com/sites/theapothecary/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/ [Last accessed 1 October 2014]
   Google Scholar
• Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med 2010;16(11):1241-7
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer TJ, Wilens TE. The drug-placebo response curve: a new method for assessing drug effects in clinical trials. J Clin Psychopharmacol 2000;20:673-9. Abstract
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd edition. Erlbaum; Hillsdale, NJ: 1988
   Google Scholar
• Artus M, van der Windt D, Jordan KP, et al. The clinical course of low back pain: a meta-analysis comparing outcomes in randomised clinical trials (RCTs) and observational studies. BMC Musculoskelet Disord 2014;15(68):1-16
   PubMedGoogle Scholar
• Available from: http://www.sec.gov/Archives/edgar/data/1588972/000119312513409707/d605505ds1.htm
   Google Scholar
• Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=1549072&highlight
   Google Scholar
• Company presentation, Durect. 2014. Slide 39 Available from: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTM0MTA2fENoaWxkSUQ9LTF8VHlwZT0z&t=1
   Google Scholar
• Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=251847&p=irol-newsArticle&ID=1963337&highlight=mnk-155
   Google Scholar
• Available from: http://www.collegiumpharma.com/press-releases/128-august-6-2014-collegium-pharmaceutical-announces-positive-top-line-data-from-phase-iii-study-of-oxycodone-deterxr-its-abuse-deterrent-extended-release-product-for-chronic-pain
   Google Scholar
• Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J Opioid Manag 2014;10(4):233-46
   PubMedGoogle Scholar
• Available from: http://www.collegiumpharma.com/productspipeline
   Google Scholar
• Colucci SV, Perrino PJ, Shram M, et al. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig 2014;34(6):421-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.medscape.com/viewarticle/824882
   Google Scholar
• Available from: http://www.pfizer.com/news/press-release/press-releasedetail/alo_02_demonstrates_significant_difference_in_pain_scores_in_chronic_low_back_pain_patients_and_lower_abuse_potential_compared_to_immediate_release_oxycodone_in_recreational_opioid_users
   Google Scholar
• Available from: http://qrxpharma.com/go.cfm?do=Page.View&pid=4
   Google Scholar
• Available from: http://www.teikokuusa.com/research.html
   Google Scholar